Top

Published in:

Open Access 01-06-2012 | Research Article

Albumin-Binding Domain Conjugate for Near-Infrared Fluorescence Lymphatic Imaging

Authors: Cynthia A. Davies-Venn, Bonnie Angermiller, Nathaniel Wilganowski, Pradip Ghosh, Barrett R. Harvey, Grace Wu, Sunkuk Kwon, Melissa B. Aldrich, Eva M. Sevick-Muraca

Published in: Molecular Imaging and Biology | Issue 3/2012

Abstract

Purpose

The aim of this study was to develop and characterize a novel peptide imaging agent for noninvasive near-infrared fluorescence imaging of protein transport by the lymphatics. An imaging agent consisting of a cyclic albumin-binding domain (cABD) peptide, with sequence, Arg-Leu-Ile-Glu-Asp-Ile-Cys-Leu-Pro-Arg-Trp-Gly-Cys-Leu-Trp-Glu-Asp-Asp-Lys, was conjugated to a near-infrared fluorophore, IRDye800CW, allowing for enhanced vascular uptake, retention, and fluorescence imaging.

Procedure

Characterization of the cABD-IRDye800 peptide conjugate was performed using fluorescence spectroscopy to assess optical properties and SDS-PAGE and Biacore binding assays to determine binding affinity and specificity. Fluorescence imaging of normal C57BL/6 mice was conducted to monitor lymphatic uptake and retention.

Results

cABD-IRDye800 exhibited approximately six times greater fluorescent yield and greater stability than indocyanine green, an agent previously used in humans to image lymphatic vasculature. The agent exhibited affinity for albumin with IC₅₀ and Kd in the nanomolar range and demonstrated superior retention characteristics within mouse lymphatics when compared with IRDye800CW.

Conclusions

cABD-IRDye800 has utility for assessing lymphatic function in mouse models of human lymphatic disease and the potential for use in clinical diagnostic imaging of the lymphatic vasculature.

Available only for authorised users

Rockson SG (2001) Lymphedema. Am J Med 110:288–295PubMedCrossRef

Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946–953PubMedCrossRef

Ferrell RE, Levinson KL, Esman JH et al (1998) Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet 7:2073–8PubMedCrossRef

Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67:295–301PubMedCrossRef

Irrthum A, Devriendt K, Chitayat D et al (2003) Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 72:1470–8PubMedCrossRef

Fang J, Dagenais SL, Erickson RP et al (2000) Mutations in FOXC2 (MFH-1), a forkhead transcription factor are responsible for hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 67:1382–1388PubMedCrossRef

Lyon MF, Glenister PH (1984) Mouse News Lett 71:26

Karkkainen MJ, Saaristo A, Jussila L et al (2001) Model for gene therapy for human hereditary lymphedema. PNAS 23:12677–82CrossRef

Francois M, Caprini A, Hosking B et al (2008) Sox18 induces development of lymphatic vasculature in mice. Nature 456:643–7PubMedCrossRef

10.

Kriederman BM, Myloyde TL, Witte MH et al (2003) FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet 10:1179–1185CrossRef

11.

Finegold DN, Schacht V, Kimak MA et al (2008) HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 6:65–8PubMedCrossRef

12.

Sharma R, Wendt JA, Rasmussen JC, Adams KE, Marshall MV, Sevick-Muraca EM (2008) New horizons for imaging lymphatic function. Ann NY Acad Sci 1131:13–36PubMedCrossRef

13.

Szuba A, Shin WS, Strauss HW, Rockson S (2003) The third circulation: radionuclide scintigraphy in the evaluation of lymphedema. J Nucl Med 44:43–57PubMed

14.

Yuan Z, Chen L, Luo Q, Zhu J, Lu H, Zhu R (2006) The role of radionuclide lymphoscintigraphy in extremity lymphedema. Ann Nucl Med 20:341–344PubMedCrossRef

15.

Witte CL, Witte MH, Unger EC et al (2000) Advances in imaging of lymph flow disorders. Radiographics 20:1697–719PubMed

16.

Marotel M, Cluzan R, Ghabboun S, Pascot M, Alliot F, Lasry JL (1998) Transaxial computer tomography of lower extremity lymphedema. Lymphology 31:180–85PubMed

17.

Lohrmann C, Foeldi E, Langer M (2009) MR imaging of the lymphatic system in patients with lipedema and lipo-lymphedema. Microvasc Res 77:335–9PubMedCrossRef

18.

Marshall MV, Rasmussen JC, Tan I-C et al (2010) Near-infrared fluorescence imaging in humans with indocyanine green: a review and update. Open Surg Oncol J 2:12–25CrossRef

19.

Craandijk A, Van Beek CA (1976) Indocyanine green fluorescence angiography of the choroid. Brit J Opthal 60:377–85CrossRef

20.

Cherrick GR, Stein SW, Leevy CM, Davidson CS (1960) Indocyanine Green: observations on its physical properties, plasma decay and hepatic extraction. J Clin Investig 39:592–600PubMedCrossRef

21.

Sevick-Muraca, EM, Sharma R, Rasmussen JC et al. (2008) Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore. Radiology 246:734–741

22.

Rasmussen JC, Tan I-C, Marshall MV, Fife CE, Sevick-Muraca EM (2009) Lymphatic imaging in humans with near-infrared fluorescence. Curr Opin Biotechnol 20:1–9CrossRef

23.

Maus EA, Tan I-C, Rasmussen JC et al. (2010) Near-infrared fluorescence lymphatic imaging of head and neck lymphedema. Head and Neck PMID: 21077150

24.

Adams KE, Rasmussen JC, Darne C et al (2010) A method to assess lymphatic response to advanced pneumatic compression device treatment of lymphedema. Biomed Opt Express 1:114–125PubMedCrossRef

25.

Rasmussen JC, Tan I-C, Maus EA et al (2010) Human lymphatic architecture and dynamic transport imaged using near-infrared fluorescence. Transl Oncol 3:362–72PubMed

26.

Tan I-C, Maus EA, Rasmussen JC et al (2011) NIR fluorescence imaging of improved lymphatic propulsion and transport following manual lymphatic drainage. Arch Phys Med Rehabil (in press)

27.

Saxena V, Sadoqi M, Shao J (2003) Degradation kinetics of indocyanine green in aqueous solution. J Pharm Sci 92:2090–97PubMedCrossRef

28.

Philip R, Penzkofer A, Baumler W, Szeimies RM, Abels C (1996) Absorption and fluorescence spectroscopic investigation of indocyanine green. J Photochem Photobiol A 96:137–38CrossRef

29.

Landsmen ML, Kwant G, Mook GA, Zijlstra WG (1976) Light-absorbing properties, stability and spectral stabilization of Indocyanine green. J Appl Physiol 40:575–583

30.

Fiehn C, Kratz F, Sass G, Muller-Ladner U, Neumann E (2008) Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis 67:1188–91PubMedCrossRef

31.

Xie D, Yao C, Wang L et al (2010) An albumin conjugated peptide exhibits potent anti-HIV activity and long in vivo half- life. Antimicrob Agents Chemother 54:191–6PubMedCrossRef

32.

Chen K, Xie J, Chen X (2009) RGD-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 8:65–73PubMed

33.

Prakash J, Bansal R, Post E, de Jagger-Krikken A, Lub de Hooge MN, Poelstra K (2009) Albumin binding and tumor vasculature determine the anti-tumor effect of 15-deoxyΔ^12,14 prostaglandin-J2 in vivo. Neoplasia 11:1348–58PubMed

34.

Lo et al (2011) Targeted human serum albumin nanoparticles for uptake in EGFR colon carcinoma. Nanomedicine (in press)

35.

Dubey PK, Singodia D, Verma RK, Vyas SP (2011) RGD modified albumin nanospheres for tumor vasculature targeting. J Pharm Pharmacol 63:33–40PubMedCrossRef

36.

Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H (2008) Specific targetting of HER2 overexpressing breast cancer cells with human serum albumin nanoparticles. Biconjugate Chem 19:2321–31CrossRef

37.

Kratz F, Mueller-Driver R, Hofmann I, Drevs J, Unger C (2000) A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 43:1253–1256PubMedCrossRef

38.

Linhult M, Binz HK, Uhlén M, Hober S (2002) Mutational analysis of interaction between albumin binding domain from streptococcal G protein and serum albumin. Protein Sci 11:206–213PubMedCrossRef

39.

Johansson (2002) Structure, specificity and mode of action for bacterial albumin binding modules. J Biol Chem 277:8114–20PubMedCrossRef

40.

Dennis M, Zhang M, Meng YG (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035–43PubMedCrossRef

41.

Nguyen A, Reyes A, Zhang M et al (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of albumin binding. Protein Eng Des Sel 19:291–297PubMedCrossRef

42.

Stork R, Muller E, Kontermann RE (2007) A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin binding domain from Streptococcal protein G. Protein Eng Des Sel 20:569–76PubMedCrossRef

43.

Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. JBC 282:12650–60CrossRef

44.

Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H (2008) Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded, trastuzumab modified human serum albumin nanoparticles. Bioconjug Chem 19:2321–31PubMedCrossRef

45.

Jonsson A, Dogan J, Herne N, Abrahmsén L, Nygren PA (2008) Engineering of a femtomolar affinity binding protein to human serum albumin. Prot Eng Des Sel 21:515–27CrossRef

46.

Trussel S, Dumelin C, Frey K, Villa A, Buller F, Neri D (2009) New strategy for the extension of the half-life of antibody fragments. Bioconjug Chem 20:2286–92PubMedCrossRef

47.

Hopp J, Hornig N, Zettlitz KA et al (2010) Effects of affinity and valency of albumin binding domain on half life. Protein Eng Des Sel 23:827–34PubMedCrossRef

48.

Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S (2010) Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine 5:525–32PubMed

49.

Vandoorne K, Addadi Y, Neeman M (2010) Visualizing vascular permeability and lymphatic drainage using labeled serum albumin. Angiogenesis 13:75–85PubMedCrossRef

50.

Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRN) using a minimal albumin binding domain. J Biol Chem 286:5234–41PubMedCrossRef

51.

Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010) Single dose toxicity study of IRDye800 CW in Spraque–Dawley rats. Mol Imaging Biol 12:583–94PubMedCrossRef

52.

Williams ATR, Winfield SA, Miller JN (1983) Relative fluorescence quantum yields using a computer controlled luminescence spectrometer. Analyst 108:1067CrossRef

53.

Sevick-Muraca EM, Lopez G, Reynolds JS, Troy TL, Hutchinson CL (1997) Fluorescence and absorption contrast mechanisms for biomedical optical imaging using frequency domain techniques. Photochem Photobiol 66:55–64PubMedCrossRef

54.

Yuk JS, Trnavsky M, McDonagh C, MacCraith B (2010) Surface plasmon-coupled emission (SPCE)-based immunoassay using a novel paraboloid array biochip. Biosens Bioelectron 25:1344–49PubMedCrossRef

55.

Holzer W, Mauerer M, Penzkofer A et al (1998) Photostability and thermal stability of indocyanine green. J Photochem Photobiol B 47:155–64PubMedCrossRef

56.

Ohnishi S, Lomnes SJ, Laurence RG, Gogbashian A, Mariani G, Frangioni JV (2005) Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Mol Imaging 4:172–181PubMed

57.

Maarek JM, Holschneider DP, Harimoto J (2000) Fluorescence of indocyanine green in blood: intensity dependence on concentration and stabilization with sodium polyaspartate. J Photochem Photobiol B 65:157–64CrossRef

58.

Ott P, Weisiger RA (1997) Nontraditional effects of protein binding and hematocrit on uptake of indocyanine green by perfused rat liver. Am J Physiol 273:G227–38PubMed

59.

Kwon S, Sevick-Muraca EM (2010) Functional lymphatic imaging in tumor-bearing mice. J Immunol Meth 360(1–2):167–172CrossRef

Title: Albumin-Binding Domain Conjugate for Near-Infrared Fluorescence Lymphatic Imaging
Authors: Cynthia A. Davies-Venn
Bonnie Angermiller
Nathaniel Wilganowski
Pradip Ghosh
Barrett R. Harvey
Grace Wu
Sunkuk Kwon
Melissa B. Aldrich
Eva M. Sevick-Muraca
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 3/2012
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-011-0499-x

At a glance: The STEP trials

Springer Medicine

Albumin-Binding Domain Conjugate for Near-Infrared Fluorescence Lymphatic Imaging

Abstract

Purpose

Procedure

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Procedure

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Microvessel Density But Not Neoangiogenesis Is Associated with 18F-FDG Uptake in Human Atherosclerotic Carotid Plaques

RGD-Conjugated Human Ferritin Nanoparticles for Imaging Vascular Inflammation and Angiogenesis in Experimental Carotid and Aortic Disease

Dual-Labeling Strategies for Nuclear and Fluorescence Molecular Imaging: A Review and Analysis

An Evaluation of 2-deoxy-2-[18F]Fluoro-D-Glucose and 3′-deoxy-3′-[18F]-Fluorothymidine Uptake in Human Tumor Xenograft Models

Spectral Unmixing Imaging of Wavelength-Responsive Fluorescent Probes: An Application for the Real-Time Report of Amyloid Beta Species in Alzheimer’s Disease

Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies